**Chapter 5**

*Molecular Understanding of Colorectal Cancer*

[120] Ryan E et al. The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Critical Reviews in Oncology/Hematology. 2017;**116**:38-57

patients with advanced cancers. Clinical Cancer Research. 2017;**23**(14):3657-3666

[129] Li Y et al. Salivary transcriptome

detection. Clinical Cancer Research.

diagnostics for oral cancer

2004;**10**(24):8442-8450

[121] Buza N, Ziai J, Hui P. Mismatch repair deficiency testing in clinical practice. Expert Review of Molecular Diagnostics. 2016;**16**(5):591-604

[122] Le DT et al. PD-1 blockade in tumors with mismatch-repair

deficiency. The New England Journal of Medicine. 2015;**372**(26):2509-2520

[123] Overman MJ et al. Nivolumab in patients with metastatic DNA mismatch

repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. The Lancet Oncology. 2017;**18**(9):1182-1191

[124] Cabel L et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews. Clinical Oncology.

[125] Hause RJ et al. Classification and characterization of microsatellite instability across 18 cancer types. Nature

Medicine. 2016;**22**(11):1342-1350

[126] Ladas I et al. Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homopolymers in tissue and liquid biopsies. Nucleic Acids Research. 2018;**46**(12):e74

[127] Millholland JM et al. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Research and Reports in Urology.

[128] Fujii T et al. Mutation-enrichment

next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from

2018;**15**(10):639-650

**78**

2012;**4**:33-40
